FMO5 and diabetic kidney disease: For example, it is found that Atorvastatin alleviated diabetic kidney disease (DKD) and diabetic nephropathies through downregulating pro-oxidant expression, including histone deacetylase (HDAC), NADPH oxidases, and Nox4, along with promoting cellular survival or proliferation by activation of the Akt/GSK3β and RhoA signalling pathway, resulting in elevated renal e-cadherin expression that indicated restored kidney function [102,103,104].